Clinical Trial Update: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for HRYZ-T102 TCR-T cell therapy targeting AFP-positive advanced hepatocellular carcinoma and other solid tumors; trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HRYZ-T102 TCR-T Cell

Snippet

Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd. | Conditions: Hepatic Cell Carcinoma | Phase 1 | Status: RECRUITING